Last reviewed · How we verify
mometasone furoate + Oxymetazoline
Mometasone furoate reduces nasal inflammation via glucocorticoid receptor activation, while oxymetazoline constricts nasal blood vessels to reduce congestion.
Mometasone furoate reduces nasal inflammation via glucocorticoid receptor activation, while oxymetazoline constricts nasal blood vessels to reduce congestion. Used for Nasal congestion and inflammation associated with allergic rhinitis or rhinosinusitis.
At a glance
| Generic name | mometasone furoate + Oxymetazoline |
|---|---|
| Also known as | NASONEX + Oxymetazoline Hydrochloride Spray |
| Sponsor | Guangzhou Women and Children's Medical Center |
| Drug class | Intranasal corticosteroid + nasal decongestant combination |
| Target | Glucocorticoid receptor (mometasone); alpha-2 adrenergic receptor (oxymetazoline) |
| Modality | Small molecule |
| Therapeutic area | Otolaryngology / Rhinology |
| Phase | FDA-approved |
Mechanism of action
Mometasone furoate is a topical corticosteroid that binds glucocorticoid receptors to suppress inflammatory cytokines and immune cell infiltration in nasal mucosa. Oxymetazoline is a selective alpha-2 adrenergic agonist that causes vasoconstriction of nasal blood vessels, reducing mucosal edema and nasal airway obstruction. The combination provides both anti-inflammatory and decongestant effects for symptomatic relief.
Approved indications
- Nasal congestion and inflammation associated with allergic rhinitis or rhinosinusitis
Common side effects
- Epistaxis (nosebleed)
- Nasal irritation or dryness
- Headache
- Pharyngeal irritation
- Rebound congestion (with prolonged oxymetazoline use)
Key clinical trials
- Study of Mometasone Furoate Nasal Spray and Oxymetazoline Nasal Spray Given Together Once A Day To Treat Seasonal Allergic Rhinitis (P04500) (PHASE2)
- Comparison of the Effects for Lightening the Shiners Among Different Treatments for Rhinitis (NA)
- Efficacy and Cost Analysis of Steroids in Treatment of Otitis Media With Effusion (PHASE4)
- Study to Assess the Effects of Allergic Rhinitis and Co-administration of Mometasone or Oxymetazoline on the Pharmacokinetics, Safety, and Tolerability of Intranasal Esketamine (PHASE1)
- Mometasone Furoate and Oxymetazoline in the Treatment of Adenoid Hypertrophy (PHASE4)
- Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: